Osteomalacia.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 18. J Bone Miner Res. 2026 Feb 3;41(2):104-111. doi: 10.1093/jbmr/zjaf148. Skeletal involvement in tumor-induced osteomalacia. Minisola S(1), Colangelo L(1), Pepe J(1), Cipriani C(1), Corsi A(2). Author information: (1)Department of Clinical, Internal, Anaesthesiologic and Cardiovascular Sciences, "Sapienza" University of Rome, 00161 Rome, Italy. (2)Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy. Tumor-induced osteomalacia (TIO) is an ultrarare paraneoplastic syndrome of abnormal phosphate and vitamin D metabolism secondary to the overproduction of fibroblast growth factor 23 by small-sized mesenchymal tumors typically located in soft tissues and bone. The tumor has adverse effects on bone and patients complain of skeletal symptoms and, in severe cases, they suffer multiple devastating fractures. Specific features may characterize the histology of tumors located in bone with respect to those found in extra-skeletal sites. Indeed, the matrix may contain foci resembling primitive cartilage and osteoid. Light microscopy of bone biopsy samples reveal accumulation of osteoid due to thickening of osteoid seams and, if tetracyclines were sequentially administrated, fluorescence microscopy reveals prolongation of the mineralization lag time. Areal BMD assessed by DXA is significantly lower at both the lumbar and femoral sites in patients with TIO and values of trabecular bone score are significantly reduced with respect to healthy individuals. Patients with TIO are also characterized by significant impairment in bone quality at both the trabecular and cortical compartment when evaluated by HR-pQCT. Successful surgical removal of the causative tumor completely reverts biochemical abnormalities. BMD accrual is impressive in the short term at the central (spine and hip) level but may take longer to improve, together with microstructural parameters, at peripheral sites (radius and tibia). Future studies should address effects of long-term treatment on quality-of-life outcomes related to irreversible events, such as vertebral fractures. This is particularly important in patients with a heavy burden due to a long-standing disease. Plain Language Summary: Tumor-induced osteomalacia is an ultrarare paraneoplastic syndrome of abnormal phosphate and vitamin D metabolism characterized by increased phosphate loss consequent to overproduction of the hormone fibroblast growth factor 23. Phosphorus is fundamental for muscle function and bone mineralization. Therefore, when values in the body are very low, there are a number of negative consequences on many skeletal aspects. In addition to skeletal pain, patients may suffer from devastating multiple fractures. When the tumor is successfully removed, biochemical and skeletal alterations are reversed. However, in those with longstanding disease and fractures, full recovery may not be complete. © The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. DOI: 10.1093/jbmr/zjaf148